What is the typical dosing for Survodutide?

Doses from clinical trials. Common doses observed in research: Titrated up to 4.8mg weekly, Various dose levels studied. Duration: Long-term use expected. Administration: Subcutaneous injection weekly.

Weight Loss

Survodutide

Also known as: BI 456906

Clinical Trials

Buy in shop

Survodutide from $272/kit

2 verified vendors, ≥99% purity, COAs included.

Compare prices

Key Facts: Survodutide

Category: Weight Loss
FDA Status: Not FDA Approved
Clinical Status: Phase 3 Clinical Trials - FDA Breakthrough Therapy Designation for MASH
Administration: Subcutaneous injection weekly
Typical Dose: Limited community data available
Frequency: See research protocols
Duration: Long-term use expected

Also Known As

BI 456906

Mechanism of Action

Survodutide activates both GLP-1 receptors (appetite suppression, glucose control) and glucagon receptors (increased energy expenditure, reduced liver fat). The glucagon component adds metabolic benefits beyond pure GLP-1 agonists.

Research Summary

Phase 2 showed 83% of patients had MASH resolution vs 18% placebo. Phase 3 SYNCHRONIZE trials for obesity expected to complete early 2026. LIVERAGE trials for MASH enrolling 3,000+ participants.

Trial Progress:Phase III

Pre

III

FDA

Dosing Information

Human Trials·Human studies conducted, not FDA approved

Typical DosingⓘDoses commonly used by people in practice, based on community reports and anecdotal experience.

Community experience

Common Dose

Limited community data available

Range

See research dosing

Frequency

See research protocols

Research DosingⓘDoses from published scientific studies and clinical trials. May include human or animal research.

Scientific studies

Doses from clinical trials

Doses from Studies

Titrated up to 4.8mg weekly

Clinical Trial Data - Phase 3 Clinical Trials ↗

Various dose levels studied

Clinical Trial Data - Phase 3 Clinical Trials ↗

Duration

Long-term use expected

Administration

Subcutaneous injection weekly

Timing & Administration

Best Time to Take

Before bed or morning (fasted)

Follow specific peptide protocol

Food Recommendation

Take on empty stomach

Why This Timing?

GH-related peptides work best on an empty stomach to maximize growth hormone release.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

●Nausea (55-75%)
●Vomiting (41%)
●Diarrhea (49%)
●Constipation
●GI effects during dose escalation
●Currently in Phase 3 trials

References

Research This Peptide Further

PubMed ClinicalTrials.gov FDA.gov

Buy in shop

Survodutide from $272/kit

2 verified vendors, ≥99% purity, COAs included.

Compare prices

Frequently Asked Questions

What does Survodutide do?

A dual GLP-1/glucagon receptor agonist in development for obesity and MASH. Has FDA Breakthrough Therapy Designation for MASH with fibrosis.

How does Survodutide work?

Is Survodutide FDA approved?

No, Survodutide is not currently FDA approved. Current status: Phase 3 Clinical Trials - FDA Breakthrough Therapy Designation for MASH

What are the side effects of Survodutide?

Reported side effects include: Nausea (55-75%), Vomiting (41%), Diarrhea (49%), Constipation, GI effects during dose escalation. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Survodutide?

Community-reported common dose: Limited community data available (See research protocols). Range: See research dosing. Administration: Subcutaneous injection weekly. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Survodutide or used in similar applications.

Retatrutide

Clinical Trials

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.

Weight Loss

Cagrilintide

Clinical Trials

A long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).

Weight Loss

Eloralintide

Clinical Trials

A next-generation oral GLP-1 receptor agonist developed by Structure Therapeutics (now Ventyx Biosciences). Shows comparable weight loss to injectable GLP-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing.

Weight Loss

Semaglutide

FDA

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

Weight Loss

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.

Weight Loss

Orforglipron

FDA

An oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo - the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.

Weight Loss

How to Use Survodutide Survodutide Alternatives Compare with Similar Browse All Peptides

Want updates on Survodutide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides